PURPOSE: Phase I trials serve a crucial role in anticancer drug development. Given the explosion in the number of both approved anticancer therapies and agents in development, we hypothesized that the characteristics of patients enrolling on phase I clinical trials is evolving. PATIENTS AND METHODS: We reviewed 476 published phase I trials over the past decade encompassing 15,100 patients and determined the following characteristics for patients enrolled: age; percentage with ECOG PS of 0, 1, or 2; sex; race; and number of prior chemotherapeutic therapies received: 0, 1, 2 or ≥ 3. We also identified the major tumor types enrolled: colorectal, lung, renal, breast, head/neck or "other". The change of patient characteristics over time as well as between the first half of studied period (period 1 = 1998-2001) and the second half period (period 2 = 2002-2006) was analyzed. RESULTS: Colorectal and lung cancer patients together comprise ~35% of all patients enrolled on phase I trials and this has not changed over the past decade. The contribution of "other" malignancies has however significantly increased over time. The proportion of patients with PS2 has declined while that of PS1 has increased. The proportion of patients with ≥3 prior therapies prior to study enrollment has also significantly increased. CONCLUSION: The shifting of patient characteristics especially as related to tumor types enrolled and number of prior therapies has important implications for future design of studies and inadequate attention to these issues may slow the accrual process.
PURPOSE: Phase I trials serve a crucial role in anticancer drug development. Given the explosion in the number of both approved anticancer therapies and agents in development, we hypothesized that the characteristics of patients enrolling on phase I clinical trials is evolving. PATIENTS AND METHODS: We reviewed 476 published phase I trials over the past decade encompassing 15,100 patients and determined the following characteristics for patients enrolled: age; percentage with ECOG PS of 0, 1, or 2; sex; race; and number of prior chemotherapeutic therapies received: 0, 1, 2 or ≥ 3. We also identified the major tumor types enrolled: colorectal, lung, renal, breast, head/neck or "other". The change of patient characteristics over time as well as between the first half of studied period (period 1 = 1998-2001) and the second half period (period 2 = 2002-2006) was analyzed. RESULTS:Colorectal and lung cancerpatients together comprise ~35% of all patients enrolled on phase I trials and this has not changed over the past decade. The contribution of "other" malignancies has however significantly increased over time. The proportion of patients with PS2 has declined while that of PS1 has increased. The proportion of patients with ≥3 prior therapies prior to study enrollment has also significantly increased. CONCLUSION: The shifting of patient characteristics especially as related to tumor types enrolled and number of prior therapies has important implications for future design of studies and inadequate attention to these issues may slow the accrual process.
Authors: A William Blackstock; James E Herndon; Electra D Paskett; Michael C Perry; Stephen L Graziano; Joseph J Muscato; Michael P Kosty; Wallace L Akerley; Jimmie Holland; Stewart Fleishman; Mark R Green Journal: J Natl Cancer Inst Date: 2002-02-20 Impact factor: 13.506
Authors: Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark Journal: JAMA Date: 2004-11-03 Impact factor: 56.272
Authors: A Italiano; C Massard; R Bahleda; A-L Vataire; E Deutsch; N Magné; J-P Pignon; G Vassal; J-P Armand; J-C Soria Journal: Ann Oncol Date: 2007-11-27 Impact factor: 32.976